Two‐year follow‐up of a prospective study of circulating regulatory T cells in renal transplant patients

San Segundo D, Fernández‐Fresnedo G, Ruiz JC, Rodrigo E, Benito MJ, Arias M, López‐Hoyos M. Two‐year follow‐up of a prospective study of circulating regulatory T cells in renal transplant patients.
Clin Transplant 2010: 24: 386–393. © 2009 John Wiley & Sons A/S. Abstract: CD4⁺CD25^highFOXP3⁺ regulatory T cells (Tregs) are involved in alloreactivity and may be associated with protection from rejection. Their quantification in peripheral blood could guide clinicians in the management of renal transplant patients. Thus, we prospectively monitored the levels and in vitro suppression of circulating Tregs in 33 renal transplant patients from deceased donors within the first two yr of transplantation. Patients received maintenance immunosuppression with tacrolimus, mofetil mycophenolate and prednisolone. Results showed that peripheral blood Tregs were significantly lower six months after transplantation and recovered to almost basal levels at first post‐transplant year. The number of circulating Tregs increased significantly over basal levels afterwards. The decrease in circulating Tregs at six months may be explained by the high load of tacrolimus, as demonstrated by the inverse correlation between the blood concentration of Tregs and tacrolimus. Likewise, nine patients treated with anti‐CD25 antibodies showed higher numbers of Tregs at six months than those that did not, although differences were not observed later. In conclusion, circulating Tregs decrease in the first six months but recover thereafter up to two yr after kidney transplantation. Such a decrease is favored by high levels of tacrolimus but not by induction protocols with anti‐CD25.